Allspring Global Investments Holdings LLC lifted its holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK – Free Report) by 53.0% in the second quarter, HoldingsChannel reports. The firm owned 75,831 shares of the biotechnology company’s stock after buying an additional 26,268 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Anika Therapeutics were worth $1,970,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in the business. BlackRock Inc. grew its holdings in shares of Anika Therapeutics by 2.1% in the third quarter. BlackRock Inc. now owns 2,459,181 shares of the biotechnology company’s stock valued at $58,527,000 after purchasing an additional 49,994 shares in the last quarter. Trigran Investments Inc. lifted its stake in Anika Therapeutics by 2.2% in the first quarter. Trigran Investments Inc. now owns 1,598,614 shares of the biotechnology company’s stock worth $45,912,000 after acquiring an additional 34,073 shares during the last quarter. Vanguard Group Inc. lifted its stake in Anika Therapeutics by 1.2% in the third quarter. Vanguard Group Inc. now owns 987,368 shares of the biotechnology company’s stock worth $23,499,000 after acquiring an additional 12,125 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Anika Therapeutics by 1.9% in the first quarter. Dimensional Fund Advisors LP now owns 978,300 shares of the biotechnology company’s stock worth $28,096,000 after acquiring an additional 18,554 shares during the last quarter. Finally, State Street Corp lifted its stake in Anika Therapeutics by 16.4% in the first quarter. State Street Corp now owns 929,498 shares of the biotechnology company’s stock worth $23,340,000 after acquiring an additional 130,930 shares during the last quarter. Institutional investors and hedge funds own 90.79% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the stock. StockNews.com assumed coverage on shares of Anika Therapeutics in a research note on Thursday, October 5th. They issued a “hold” rating for the company. Barrington Research boosted their price objective on shares of Anika Therapeutics from $24.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Stephens reduced their price objective on shares of Anika Therapeutics from $28.00 to $23.00 and set an “equal weight” rating for the company in a research report on Thursday, August 10th.
Anika Therapeutics Trading Up 0.4 %
Shares of NASDAQ:ANIK opened at $21.20 on Tuesday. The company has a market capitalization of $310.18 million, a PE ratio of -12.54 and a beta of 0.70. Anika Therapeutics, Inc. has a twelve month low of $16.54 and a twelve month high of $32.51. The firm has a 50 day simple moving average of $18.54 and a 200-day simple moving average of $22.52.
Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.21. Anika Therapeutics had a negative net margin of 13.68% and a negative return on equity of 3.53%. The firm had revenue of $44.30 million during the quarter, compared to the consensus estimate of $40.61 million. As a group, equities research analysts predict that Anika Therapeutics, Inc. will post -0.78 EPS for the current fiscal year.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally.
- Five stocks we like better than Anika Therapeutics
- How to Build Wealth with the Dividend Aristocrat Index
- These 5 small-cap impact stocks are making social change
- Options Trading – Understanding Strike Price
- Alphabet slays its earnings but falls on its sword with cloud
- How to Invest in Communication Stocks
- There’s nothing artificial about NVIDIA’s relationship with AI
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.